In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, R&D directors, and commercial directors from gastrointestinal stent producers and medical device OEMs were examples of supply-side sources. Board-certified gastroenterologists, interventional endoscopists, general surgeons, oncology specialists, medical directors of endoscopy facilities, procurement leads from hospitals, ambulatory surgical centers, and specialty clinics were among the demand-side sources. Market segmentation, product pipeline timelines, clinical acceptance trends, price strategies, reimbursement dynamics, and material preferences (Nitinol, stainless steel, polyurethane, silicone) were all confirmed by primary research.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and procedure volume analysis. The methodology included:
Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America
Product mapping across metallic stents, plastic stents, self-expandable stents, and covered stents
Application-based analysis covering esophageal stents, gastric stents, duodenal stents, and colorectal stents
Material segmentation analysis across Nitinol, stainless steel, polyurethane, and silicone
Analysis of reported and modeled annual revenues specific to gastrointestinal stent portfolios
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (procedure volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations